×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

HIV Diagnostics Market Analysis

ID: MRFR/MED/8279-HCR
200 Pages
Rahul Gotadki
October 2025

Global HIV Diagnostics Market Research Report By Test Type (Antibody Tests, Antigen Tests, Nucleic Acid Tests), By End User (Hospitals, Diagnostic Laboratories, Home Care Settings), By Product Type (Tests Kits, Instruments, Software), By Technology (Elisa, Rapid Testing, Polymerase Chain Reaction) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)-Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

HIV Diagnostics Market Infographic
Purchase Options

Market Analysis

HIV Diagnostics Market (Global, 2025)

Introduction

The HIV diagnostics market is undergoing significant change, as technological advancements and increased awareness of the threat of HIV and AIDS spur demand for new and better testing solutions. A growing focus on early detection and treatment has prompted the widespread adoption of rapid diagnostics and point-of-care testing. Further shaping the market is the integration of digital health, which makes remote monitoring and data management easier and improves patient outcomes. The rising prevalence of HIV in some regions also highlights the need for effective diagnostic tools, driving the public and private sectors to invest in research and development. The market will continue to evolve as it grapples with regulatory challenges and the need for cost-effective solutions. In the end, the market is likely to see a dynamic interplay between traditional and novel diagnostics, with the ultimate goal of reducing the global burden of HIV.

PESTLE Analysis

Political
The market for AIDS diagnostics in 2025 will be largely influenced by government policies designed to combat the AIDS epidemic. For example, the U.S. government has allocated approximately $1.1 billion to HIV prevention and treatment programs, which includes funding for diagnostics. The same is true for other developed countries. Moreover, international organizations, such as the Global Fund, have pledged $4.5 billion to support HIV/AIDS prevention and treatment in low- and middle-income countries, which highlights the importance of accessible diagnostics in these regions.
Economic
The HIV diagnostics market in 2025 will be affected by rising healthcare costs, which are projected to reach $4.3 trillion in the United States alone. This increase is partly due to the need for more advanced diagnostic tools to improve the treatment of patients. The cost of testing has fallen by up to 30% over the last five years, which makes it more affordable for both health care professionals and patients. In developing countries, the cost of testing is now around $10 per test.
Social
The social attitude towards the test and the treatment has changed a lot. It is now estimated that 70 per cent of the population in the high-prevalence areas is in favour of routine testing. It is the result of a marked increase in public information and education, which has led to a 25 per cent increase in the number of people tested each year. Also the stigma has been greatly reduced, and a recent survey shows that 60 per cent of the population believe that people living with HIV should have the same rights as people without the virus.
Technological
The market for diagnostics for AIDS is a major field of development. The introduction of rapid test kits which give results in less than 30 minutes has been particularly noteworthy. By 2025, it is estimated that over 50 million such kits will have been sold. This represents an increase of 40 per cent over the figure for 2024. In addition, the development of molecular diagnostics, such as PCR tests, have greatly improved the accuracy of the diagnosis. Moreover, the accuracy of the tests is over 95 per cent, which enables the detection of AIDS at an earlier stage and the initiation of treatment.
Legal
Legal frameworks for the diagnosis of AIDS are becoming more and more solid. Forty-five countries have enacted laws requiring the availability of a HIV test. The World Health Organization’s guidelines for 2025 require that at least ninety per cent of all people living with HIV know their status. This has resulted in a higher degree of surveillance and regulation in the field of diagnostics. Also, there are moves afoot to have the patent laws reviewed in order to make way for generic test-kits, which would lower the costs and increase access.
Environmental
The disposal of medical waste is a subject that is increasingly being addressed in the field of HIV diagnosis. By 2025 it is estimated that medical waste from hospitals will reach 16 million tons per year, a large part of which is due to diagnostics. In order to limit the impact on the environment, a large number of hospitals are implementing sustainable practices such as the proper disposal of medical waste and the implementation of a proper disposal procedure. In the coming years, the number of hospitals that have introduced a disposal procedure that is more friendly to the environment will rise to 30%.

Porter's Five Forces

Threat of New Entrants
The AIDS diagnostics market in 2025 is characterized by moderate barriers to entry. New players will have to overcome the technological and regulatory hurdles. But the growing demand for new diagnostics and technological innovations may encourage new entrants. The existing players have strong brand loyalty and distribution networks, which may discourage new entrants. However, the potential for high profits may also encourage some to enter the market.
Bargaining Power of Suppliers
Suppliers in the HI market generally have low bargaining power because of the availability of multiple sources for raw materials and components. There are many suppliers in the market, limiting their ability to influence prices. Also, many of the companies that make diagnostic products have the flexibility to change suppliers or even to produce components themselves, which reduces suppliers’ power even further.
Bargaining Power of Buyers
In the HIV diagnostics market, the buyers are the hospitals, clinics, and governmental agencies. The buyers have a high degree of bargaining power. The buyers can bargain for lower prices and better terms of payment, because of the increased focus on cost-effectiveness and the availability of more diagnostic choices. The buyers can also compare products, enhancing their bargaining power. This makes it essential for companies to offer both good prices and added-value services.
Threat of Substitutes
The threat of substitutes on the HIV diagnostics market is moderate. There are other testing methods and devices, such as home testing kits and rapid tests, but the sensitivity and specificity of the laboratory tests are still important. But as technology develops and new methods of testing are developed, the threat of substitutes may increase, forcing existing players to continuously improve.
Competitive Rivalry
Competition in the market for HIV diagnostics is high, with a large number of established players and a constant stream of new technology. Product differentiation and innovation are used to capture market share. Competition is further intensified by the need for continual improvement in diagnostic accuracy and speed.

SWOT Analysis

Strengths

  • Advancements in technology leading to more accurate and faster diagnostic tests.
  • Increased awareness and education about HIV leading to higher testing rates.
  • Strong support from government and non-governmental organizations for HIV testing initiatives.

Weaknesses

  • High costs associated with some advanced diagnostic technologies.
  • Limited access to testing in rural and underserved areas.
  • Stigma associated with HIV testing may deter individuals from seeking diagnosis.

Opportunities

  • Growing demand for home-based and point-of-care testing solutions.
  • Potential for partnerships with tech companies to enhance diagnostic capabilities.
  • Expansion into emerging markets with rising HIV prevalence rates.

Threats

  • Competition from alternative diagnostic methods and technologies.
  • Regulatory challenges and changes in healthcare policies affecting market dynamics.
  • Economic downturns that may limit funding for HIV testing programs.

Summary

The market for the diagnosis of AIDS in 2025 will be characterized by the strong growth of technological development and the growing awareness of the public. However, obstacles to access, such as high costs and stigma, will persist. Opportunities for growth will come from home testing and from alliances with technology companies. Threats from competition and regulatory changes will threaten the stability of the market. Strategic focus on removing obstacles and exploiting opportunities will be crucial for the participants in this developing market.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

FAQs

What is the projected market valuation of the HIV Diagnostics Market by 2035?

The HIV Diagnostics Market is projected to reach a valuation of 5.089 USD Billion by 2035.

What was the market valuation of the HIV Diagnostics Market in 2024?

In 2024, the overall market valuation was 3.288 USD Billion.

What is the expected CAGR for the HIV Diagnostics Market during the forecast period 2025 - 2035?

The expected CAGR for the HIV Diagnostics Market during the forecast period 2025 - 2035 is 4.05%.

Which companies are considered key players in the HIV Diagnostics Market?

Key players in the HIV Diagnostics Market include Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, among others.

What are the main segments of the HIV Diagnostics Market?

The main segments of the HIV Diagnostics Market include Test Type, End User, Product Type, and Technology.

How did the Antibody Tests segment perform in 2024?

The Antibody Tests segment was valued at 1.5 USD Billion in 2024 and is projected to grow to 2.3 USD Billion.

What is the projected growth for the Nucleic Acid Tests segment by 2035?

The Nucleic Acid Tests segment is expected to grow from 0.888 USD Billion in 2024 to 1.389 USD Billion by 2035.

Which end user segment is anticipated to have the highest growth?

The Hospitals segment is anticipated to grow from 1.5 USD Billion in 2024 to 2.3 USD Billion by 2035.

What is the expected valuation for the Software product type by 2035?

The Software product type is projected to reach a valuation of 0.989 USD Billion by 2035.

How does the market for Rapid Testing technology compare to other technologies?

The Rapid Testing technology segment is expected to grow from 1.2 USD Billion in 2024 to 1.8 USD Billion by 2035, indicating robust demand.

Market Summary

As per MRFR analysis, the HIV Diagnostics Market was estimated at 3.288 USD Billion in 2024. The HIV Diagnostics industry is projected to grow from 3.421 USD Billion in 2025 to 5.089 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.05 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The HIV Diagnostics Market is experiencing robust growth driven by technological advancements and increasing awareness.

  • Technological advancements in diagnostics are enhancing the accuracy and speed of HIV testing. North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for HIV diagnostics. Antibody tests continue to dominate the market, whereas nucleic acid tests are witnessing the highest growth rates. The rising prevalence of HIV and government initiatives are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 3.288 (USD Billion)
2035 Market Size 5.089 (USD Billion)
CAGR (2025 - 2035) 4.05%
Largest Regional Market Share in 2024 North America

Major Players

<p><a href="https://www.abbott.com/product-list.html">Abbott Laboratories</a> (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Becton Dickinson and Company (US), Hologic, Inc. (US), Cepheid (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US)</p>

Market Trends

The HIV Diagnostics Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing awareness of the disease. The integration of innovative diagnostic tools, such as rapid tests and point-of-care devices, appears to enhance accessibility and efficiency in testing. Furthermore, the growing emphasis on early detection and treatment is likely to propel demand for these diagnostic solutions. As healthcare systems worldwide adapt to the evolving landscape of HIV management, the market is poised for substantial growth, reflecting a commitment to improving patient outcomes and reducing transmission rates. In addition, the rising prevalence of HIV in various regions underscores the necessity for effective diagnostic measures. Public health initiatives and government support seem to play a crucial role in promoting testing and awareness campaigns. This environment fosters collaboration among stakeholders, including healthcare providers, researchers, and policymakers, to develop comprehensive strategies for combating the epidemic. The HIV Diagnostics Market, therefore, stands at a pivotal juncture, where innovation and collaboration may significantly influence its trajectory in the coming years.

Technological Advancements in Diagnostics

The HIV Diagnostics Market is witnessing a surge in technological innovations, particularly in the development of rapid testing methods. These advancements facilitate quicker results, enabling timely interventions and treatment. Moreover, the emergence of digital health solutions, such as mobile applications for monitoring and managing HIV, indicates a shift towards more integrated healthcare approaches.

Increased Focus on Preventive Healthcare

There is a growing emphasis on preventive healthcare strategies within the HIV Diagnostics Market. This trend reflects a broader understanding of the importance of early detection and regular testing. Public health campaigns are increasingly promoting routine screenings, which may lead to higher testing rates and improved health outcomes for individuals at risk.

Expansion of Point-of-Care Testing

The expansion of point-of-care testing is reshaping the HIV Diagnostics Market by making testing more accessible, especially in remote or underserved areas. This trend suggests a move towards decentralized healthcare, where patients can receive immediate results and care, thereby enhancing the overall efficiency of HIV management.

HIV Diagnostics Market Market Drivers

Rising Prevalence of HIV

The increasing prevalence of HIV infections worldwide is a primary driver of the HIV Diagnostics Market. According to recent estimates, approximately 38 million people are living with HIV, with a significant number unaware of their status. This underscores the urgent need for effective diagnostic tools to identify and manage the disease. The rising number of new infections, particularly in regions with limited access to healthcare, further amplifies the demand for innovative diagnostic solutions. As awareness campaigns and testing initiatives expand, the market for HIV diagnostics is likely to experience substantial growth. The need for timely and accurate testing is critical in controlling the spread of HIV, thereby propelling the HIV Diagnostics Market forward.

Growing Awareness and Education

The growing awareness and education surrounding HIV/AIDS are pivotal in driving the HIV Diagnostics Market. Increased public knowledge about the importance of early detection and treatment has led to a rise in testing rates. Educational campaigns, often spearheaded by health organizations, aim to destigmatize HIV testing and encourage individuals to know their status. This shift in perception is crucial, as it fosters a culture of proactive health management. In recent years, the number of individuals seeking testing has surged, indicating a positive trend towards early diagnosis. As awareness continues to spread, the demand for HIV diagnostic tools is expected to rise, thereby enhancing the market landscape.

Emerging Markets and Accessibility

Emerging markets are becoming increasingly important in the HIV Diagnostics Market. As economies develop, there is a growing focus on improving healthcare infrastructure, which includes enhancing access to HIV testing. Countries in regions such as sub-Saharan Africa and parts of Asia are witnessing a surge in demand for affordable and effective diagnostic solutions. The expansion of healthcare services in these areas is likely to drive the adoption of innovative testing methods. Furthermore, partnerships between governments and private sectors are facilitating the distribution of diagnostic tools, making them more accessible to underserved populations. This trend suggests a promising future for the HIV Diagnostics Market as it adapts to meet the needs of diverse populations.

Government Initiatives and Funding

Government initiatives aimed at combating HIV/AIDS play a crucial role in shaping the HIV Diagnostics Market. Many countries have implemented national strategies to increase testing and treatment accessibility, often backed by substantial funding. For instance, public health campaigns and partnerships with non-governmental organizations have been established to promote awareness and facilitate testing. In 2023, funding for HIV-related programs reached billions of dollars, reflecting a commitment to reducing the incidence of HIV. Such investments not only enhance the availability of diagnostic tools but also encourage research and development in the field. As governments continue to prioritize HIV prevention and treatment, the market for diagnostics is expected to expand significantly.

Technological Innovations in Testing

Technological advancements in diagnostic testing are transforming the HIV Diagnostics Market. Innovations such as rapid testing kits, molecular diagnostics, and point-of-care testing devices are enhancing the speed and accuracy of HIV detection. The introduction of these technologies has led to a notable increase in testing rates, as they provide results within minutes and can be used in various settings, including remote areas. The market for rapid HIV tests alone is projected to grow significantly, driven by the demand for user-friendly and efficient testing solutions. As technology continues to evolve, it is likely that new diagnostic methods will emerge, further propelling the growth of the HIV Diagnostics Market.

Market Segment Insights

By Test Type: Antibody Tests (Largest) vs. Nucleic Acid Tests (Fastest-Growing)

<p>The HIV Diagnostics Market consists of various test types, notably Antibody Tests, Antigen Tests, and Nucleic Acid Tests. Antibody Tests dominate the market due to their widespread usage, accounting for a significant share. These tests are crucial for their cost-effectiveness and simplicity in point-of-care settings, making them the preferred choice for initial screening. Antigen Tests follow in popularity, offering quicker results but are less widely used, while Nucleic Acid Tests, although representing a smaller share, are gaining traction for their high sensitivity and specificity, which are vital in early detection and treatment initiation.</p>

<p>Nucleic Acid Tests (Emerging) vs. Antibody Tests (Dominant)</p>

<p>Antibody Tests have long been established as the dominant testing method in the HIV Diagnostics Market, primarily due to their ease of use and effectiveness in initial screenings. These tests are typically used in various healthcare settings, from laboratories to remote clinics. In contrast, Nucleic Acid Tests, while currently an emerging segment, are recognized for their capacity to detect HIV earlier than other testing methods, which is particularly important in controlling the spread of the virus. Their ability to provide quicker and more accurate diagnoses, especially in high-risk populations, positions them for substantial growth. As technology advances, Nucleic Acid Tests are likely to become more accessible, further enhancing their market share.</p>

By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

<p>Within the HIV diagnostics market, the distribution of market share among end users is predominantly led by hospitals, which hold a significant share due to their extensive testing capabilities and resources. Following hospitals, diagnostic laboratories are emerging rapidly, drawing attention for their specialized services and efficiency in processing HIV tests. Home care settings, while growing, currently represent a smaller portion of the market as they capitalize on the convenience of testing at home. Overall, <a href="https://www.marketresearchfuture.com/reports/hospital-information-system-market-10732">hospitals </a>dominate the landscape as comprehensive healthcare providers.</p>

<p>End User Segment: Hospitals (Dominant) vs. Home Care Settings (Emerging)</p>

<p>Hospitals are the dominant force in the HIV diagnostics market, leveraging advanced technology, skilled personnel, and integrated healthcare services to drive effective HIV testing and management. They benefit from established relationships with patients and healthcare providers, ensuring high patient turnover and access to diverse diagnostic tools. On the contrary, home care settings are emerging as a popular choice among patients seeking convenience and privacy in their testing processes. While these settings facilitate a shift toward decentralized healthcare, they face challenges such as compliance, regulatory considerations, and the need for reliable technology to ensure accurate and timely results.</p>

By Product Type: Test Kits (Largest) vs. Instruments (Fastest-Growing)

<p>In the HIV Diagnostics Market, the segment of Test Kits holds a substantial share, making it the largest contributor to the market. This segment is comprised of various types of diagnostic tests, including rapid tests and laboratory-based tests, showcasing a robust demand driven by increasing testing initiatives globally. On the other hand, the <a href="https://www.marketresearchfuture.com/reports/cardiac-surgery-instruments-market-2856">Instruments </a>segment, while currently smaller in market share, is experiencing rapid growth due to advancements in technology and automation in testing processes, driving efficiency and accuracy in HIV diagnostics.</p>

<p>Test Kits: Dominant vs. Instruments: Emerging</p>

<p>Test Kits are the dominant force in the HIV Diagnostics Market, characterized by their widespread use and accessibility. They offer rapid results, which is essential for timely diagnosis and treatment initiation. The versatility and adaptability of test kits to various settings, including at-home testing, make them highly preferable among healthcare providers. In contrast, the Instruments segment is emerging, fueled by innovation in diagnostic technology that enhances the precision and speed of testing. This segment includes advanced diagnostic machinery that is becoming increasingly crucial in laboratory settings, contributing to a more organized and reliable testing environment.</p>

By Technology: ELISA (Largest) vs. Rapid Testing (Fastest-Growing)

<p>In the HIV Diagnostics Market, the technology segment showcases a diverse distribution of methods, with ELISA leading in market share due to its reliability and established presence in laboratories for HIV detection. Rapid Testing, while having a smaller current share, is rapidly gaining traction owing to its convenience and immediate results, appealing significantly to both healthcare providers and patients looking for swift diagnosis. Polymerase Chain Reaction (PCR) technology also plays a vital role, particularly in confirming infections during early stages and for quantifying viral load, but its adoption is comparatively niche. As advancements in diagnostic technologies continue, the market is witnessing robust growth driven by factors such as increasing awareness about HIV/AIDS, rising prevalence of the disease, and the need for early diagnosis. The shift towards home-based testing and point-of-care testing is reshaping patient access to timely diagnostics, leading to a decline in conventional testing methods, such as PCR. Furthermore, innovations in technology, including digital health integration, are expected to enhance patient engagement and streamline testing processes, ultimately expanding the overall market reach of the HIV diagnostics segment.</p>

<p>HIV Testing Technology: ELISA (Dominant) vs. Rapid Testing (Emerging)</p>

<p>Within the HIV diagnostics technology landscape, ELISA remains the dominant force, celebrated for its high sensitivity and specificity, making it a preferred choice for large-scale screenings. The process involves multiple steps and requires laboratory settings, which align well with regular health check-ups and preventive healthcare measures. Meanwhile, Rapid Testing is emerging significantly, providing results in as little as 20 minutes and thus catering to a growing demand for immediate feedback on HIV status. While ELISA is preferred for its accuracy in clinical settings, Rapid Testing, with its user-friendly approach and ability to reach underserved populations, marks a necessary evolution in HIV diagnostics, ensuring broader access. The convergence of these technologies showcases a comprehensive approach to managing HIV diagnoses effectively.</p>

Get more detailed insights about HIV Diagnostics Market Research Report-Forecast to 2035

Regional Insights

The Regional analysis of the Global HIV Diagnostics Market reveals significant market valuations and growth trends across various regions. In 2024, North America is projected to hold a valuation of 1.32 USD Billion, demonstrating majority holding in the overall market and underscoring its importance with advanced healthcare infrastructure and high awareness levels.

Europe follows closely with a valuation of 0.88 USD Billion and is significant due to its robust research capabilities and healthcare policies. The APAC region, valued at 0.82 USD Billion, is rapidly emerging due to increased screening initiatives and population awareness, while South America and MEA, with valuations of 0.15 USD Billion and 0.12 USD Billion respectively, present opportunities for growth driven by improving healthcare access and education.

The collective Global HIV Diagnostics Market revenue is expected to reach 3.29 USD Billion in 2024, reflecting the industry's adaptation to local needs and the varying prevalence of HIV across these regions. As such, market segmentation across these regions is critical for understanding regional dynamics and the tailored approaches required for effectively managing HIV diagnostics.

HIV Diagnostics Market Region

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Key Players and Competitive Insights

The Global HIV Diagnostics Market is characterized by a diverse and competitive landscape, driven by a growing emphasis on early diagnosis, increased funding for HIV-related initiatives, and rising awareness of the importance of HIV testing. The market comprises a range of players, including large multinational corporations, mid-sized companies, and specialized firms focusing on innovative diagnostic solutions.

The competitive dynamics are influenced by advancements in technology, regulatory pathways, and evolving healthcare policies in various regions. This market landscape becomes further complicated with the emergence of new players and partnerships aimed at delivering more accurate, rapid, and cost-effective testing options. Companies are increasingly investing in research and development to enhance their product portfolios and meet the unique needs of diverse populations around the globe.

Abbott Laboratories is a significant player in the Global HIV Diagnostics Market, showcasing a strong market presence with a wide range of diagnostic solutions. The company is recognized for its robust portfolio that offers both rapid and laboratory-based testing options. Abbott Laboratories has achieved a notable reputation for innovation, particularly with its advanced testing technologies that not only ensure accuracy but also cater to different testing environments.

The company’s established brand equity and extensive distribution networks contribute to its competitive advantage in reaching healthcare facilities worldwide. Furthermore, its commitment to continuous improvement in product quality and adhering to regulatory standards reflects Abbott's strengths within the global context, positioning it as a leader in the HIV diagnostics sector. Thermo Fisher Scientific has made significant strides in the Global HIV Diagnostics Market through its comprehensive suite of diagnostic products and services.

The company is known for its high-quality assays and testing kits, which are essential tools in HIV research and clinical diagnostics. Thermo Fisher has garnered a strong market presence due to its innovative approaches and commitment to developing advanced technologies that improve detection and monitoring of HIV. The company's strengths lie in its extensive research capabilities, strong collaborative efforts, and strategic mergers and acquisitions, allowing it to broaden its product offerings and enhance its market footprint.

By continually evolving its solutions and investing in cutting-edge technology, Thermo Fisher Scientific reinforces its position as a key player in the global arena focused on providing reliable and efficient HIV diagnostic solutions.

Key Companies in the HIV Diagnostics Market market include

Industry Developments

  • Q2 2024: Chembio Diagnostics Announces FDA 510(k) Clearance for DPP HIV-Syphilis System Chembio Diagnostics received FDA 510(k) clearance for its DPP HIV-Syphilis System, a point-of-care test designed to simultaneously detect HIV and syphilis antibodies, expanding its diagnostic portfolio in the U.S. market.
  • Q2 2024: OraSure Technologies Announces Launch of OraQuick HIV Self-Test in the United Kingdom OraSure Technologies launched its OraQuick HIV Self-Test in the UK, providing consumers with a rapid, at-home HIV testing option and expanding the company's international reach.
  • Q3 2024: bioLytical Laboratories Receives CE Mark for INSTI Multiplex HIV-1/2 Syphilis Antibody Test bioLytical Laboratories received CE Mark approval for its INSTI Multiplex HIV-1/2 Syphilis Antibody Test, allowing commercialization of the rapid diagnostic test across the European Economic Area.
  • Q3 2024: Abbott launches new Alinity m HIV-1 test in Europe Abbott announced the European launch of its Alinity m HIV-1 test, a molecular diagnostic assay designed for high-throughput HIV-1 viral load monitoring, enhancing its molecular diagnostics portfolio.
  • Q4 2024: MedMira Receives Health Canada Approval for Multiplo Rapid HIV/HCV Antibody Test MedMira received Health Canada approval for its Multiplo Rapid HIV/HCV Antibody Test, enabling the company to market its dual rapid test for HIV and hepatitis C in Canada.
  • Q4 2024: Cepheid and FIND Announce Partnership to Expand Access to HIV Viral Load Testing in Africa Cepheid and the Foundation for Innovative New Diagnostics (FIND) entered a partnership to increase access to Cepheid's Xpert HIV-1 Viral Load test in sub-Saharan Africa, aiming to improve HIV management in resource-limited settings.
  • Q1 2025: Chembio Diagnostics Announces $10 Million Private Placement Financing Chembio Diagnostics completed a $10 million private placement financing round to support the commercialization and development of its rapid diagnostic tests, including those for HIV.
  • Q1 2025: bioLytical Laboratories Expands Manufacturing Facility to Meet Growing Demand for HIV Rapid Tests bioLytical Laboratories announced the expansion of its manufacturing facility in Canada to increase production capacity for its HIV rapid diagnostic tests, responding to rising global demand.
  • Q2 2025: Roche receives WHO prequalification for cobas HIV-1/2 Qualitative Test Roche received World Health Organization (WHO) prequalification for its cobas HIV-1/2 Qualitative Test, supporting broader adoption of the test in low- and middle-income countries.
  • Q2 2025: OraSure Technologies Appoints New Chief Commercial Officer OraSure Technologies appointed a new Chief Commercial Officer to lead the company's global commercial strategy, including the expansion of its HIV diagnostics business.
  • Q2 2025: MedMira Signs Distribution Agreement with Major U.S. Healthcare Provider for HIV Rapid Tests MedMira signed a distribution agreement with a major U.S. healthcare provider to supply its rapid HIV tests, expanding the company's presence in the U.S. diagnostics market.
  • Q3 2025: bioLytical Laboratories Receives FDA Clearance for INSTI HIV-1/2 Antibody Test bioLytical Laboratories received FDA clearance for its INSTI HIV-1/2 Antibody Test, enabling the company to market its rapid HIV test in the United States.

Future Outlook

HIV Diagnostics Market Future Outlook

<p>The HIV Diagnostics Market is projected to grow at a 4.05% CAGR from 2024 to 2035, driven by technological advancements, increasing awareness, and rising healthcare investments.</p>

New opportunities lie in:

  • <p>Development of rapid point-of-care testing kits for remote areas.</p><p>Integration of AI-driven analytics for personalized treatment plans.</p><p>Expansion of telehealth services for remote patient monitoring and consultations.</p>

<p>By 2035, the market is expected to achieve substantial growth, enhancing global access to HIV diagnostics.</p>

Market Segmentation

HIV Diagnostics Market End User Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Home Care Settings

HIV Diagnostics Market Test Type Outlook

  • Antibody Tests
  • Antigen Tests
  • Nucleic Acid Tests

HIV Diagnostics Market Technology Outlook

  • Elisa
  • Rapid Testing
  • Polymerase Chain Reaction

HIV Diagnostics Market Product Type Outlook

  • Tests Kits
  • Instruments
  • Software

Report Scope

MARKET SIZE 20243.288(USD Billion)
MARKET SIZE 20253.421(USD Billion)
MARKET SIZE 20355.089(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)4.05% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesIntegration of point-of-care testing technologies enhances accessibility in the HIV Diagnostics Market.
Key Market DynamicsTechnological advancements and regulatory changes drive innovation and competition in the HIV diagnostics market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the HIV Diagnostics Market by 2035?

The HIV Diagnostics Market is projected to reach a valuation of 5.089 USD Billion by 2035.

What was the market valuation of the HIV Diagnostics Market in 2024?

In 2024, the overall market valuation was 3.288 USD Billion.

What is the expected CAGR for the HIV Diagnostics Market during the forecast period 2025 - 2035?

The expected CAGR for the HIV Diagnostics Market during the forecast period 2025 - 2035 is 4.05%.

Which companies are considered key players in the HIV Diagnostics Market?

Key players in the HIV Diagnostics Market include Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, among others.

What are the main segments of the HIV Diagnostics Market?

The main segments of the HIV Diagnostics Market include Test Type, End User, Product Type, and Technology.

How did the Antibody Tests segment perform in 2024?

The Antibody Tests segment was valued at 1.5 USD Billion in 2024 and is projected to grow to 2.3 USD Billion.

What is the projected growth for the Nucleic Acid Tests segment by 2035?

The Nucleic Acid Tests segment is expected to grow from 0.888 USD Billion in 2024 to 1.389 USD Billion by 2035.

Which end user segment is anticipated to have the highest growth?

The Hospitals segment is anticipated to grow from 1.5 USD Billion in 2024 to 2.3 USD Billion by 2035.

What is the expected valuation for the Software product type by 2035?

The Software product type is projected to reach a valuation of 0.989 USD Billion by 2035.

How does the market for Rapid Testing technology compare to other technologies?

The Rapid Testing technology segment is expected to grow from 1.2 USD Billion in 2024 to 1.8 USD Billion by 2035, indicating robust demand.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
    2. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
      5. Forecasting Model
      6. Market Size Estimation
      7. Data Triangulation
      8. Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS
    1. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    2. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
      3. COVID-19 Impact Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. Healthcare, BY Test Type (USD Billion)
      1. Antibody Tests
      2. Antigen Tests
      3. Nucleic Acid Tests
    2. Healthcare, BY End User (USD Billion)
      1. Hospitals
      2. Diagnostic Laboratories
      3. Home Care Settings
    3. Healthcare, BY Product Type (USD Billion)
      1. Tests Kits
      2. Instruments
      3. Software
    4. Healthcare, BY Technology (USD Billion)
      1. Elisa
      2. Rapid Testing
      3. Polymerase Chain Reaction
    5. Healthcare, BY Region (USD Billion)
      1. North America
      2. Europe
      3. APAC
      4. South America
      5. MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Healthcare
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Healthcare
      7. Key developments and growth strategies
      8. Major Players Financial Matrix
    2. Company Profiles
      1. Abbott Laboratories (US)
      2. Roche Diagnostics (CH)
      3. Thermo Fisher Scientific (US)
      4. Siemens Healthineers (DE)
      5. Becton Dickinson and Company (US)
      6. Hologic, Inc. (US)
      7. Cepheid (US)
      8. Bio-Rad Laboratories (US)
      9. Ortho Clinical Diagnostics (US)
    3. Appendix
      1. References
      2. Related Reports 6 LIST OF FIGURES
    4. MARKET SYNOPSIS
    5. NORTH AMERICA MARKET ANALYSIS
    6. US MARKET ANALYSIS BY TEST TYPE
    7. US MARKET ANALYSIS BY END USER
    8. US MARKET ANALYSIS BY PRODUCT TYPE
    9. US MARKET ANALYSIS BY TECHNOLOGY
    10. CANADA MARKET ANALYSIS BY TEST TYPE
    11. CANADA MARKET ANALYSIS BY END USER
    12. CANADA MARKET ANALYSIS BY PRODUCT TYPE
    13. CANADA MARKET ANALYSIS BY TECHNOLOGY
    14. EUROPE MARKET ANALYSIS
    15. GERMANY MARKET ANALYSIS BY TEST TYPE
    16. GERMANY MARKET ANALYSIS BY END USER
    17. GERMANY MARKET ANALYSIS BY PRODUCT TYPE
    18. GERMANY MARKET ANALYSIS BY TECHNOLOGY
    19. UK MARKET ANALYSIS BY TEST TYPE
    20. UK MARKET ANALYSIS BY END USER
    21. UK MARKET ANALYSIS BY PRODUCT TYPE
    22. UK MARKET ANALYSIS BY TECHNOLOGY
    23. FRANCE MARKET ANALYSIS BY TEST TYPE
    24. FRANCE MARKET ANALYSIS BY END USER
    25. FRANCE MARKET ANALYSIS BY PRODUCT TYPE
    26. FRANCE MARKET ANALYSIS BY TECHNOLOGY
    27. RUSSIA MARKET ANALYSIS BY TEST TYPE
    28. RUSSIA MARKET ANALYSIS BY END USER
    29. RUSSIA MARKET ANALYSIS BY PRODUCT TYPE
    30. RUSSIA MARKET ANALYSIS BY TECHNOLOGY
    31. ITALY MARKET ANALYSIS BY TEST TYPE
    32. ITALY MARKET ANALYSIS BY END USER
    33. ITALY MARKET ANALYSIS BY PRODUCT TYPE
    34. ITALY MARKET ANALYSIS BY TECHNOLOGY
    35. SPAIN MARKET ANALYSIS BY TEST TYPE
    36. SPAIN MARKET ANALYSIS BY END USER
    37. SPAIN MARKET ANALYSIS BY PRODUCT TYPE
    38. SPAIN MARKET ANALYSIS BY TECHNOLOGY
    39. REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
    40. REST OF EUROPE MARKET ANALYSIS BY END USER
    41. REST OF EUROPE MARKET ANALYSIS BY PRODUCT TYPE
    42. REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
    43. APAC MARKET ANALYSIS
    44. CHINA MARKET ANALYSIS BY TEST TYPE
    45. CHINA MARKET ANALYSIS BY END USER
    46. CHINA MARKET ANALYSIS BY PRODUCT TYPE
    47. CHINA MARKET ANALYSIS BY TECHNOLOGY
    48. INDIA MARKET ANALYSIS BY TEST TYPE
    49. INDIA MARKET ANALYSIS BY END USER
    50. INDIA MARKET ANALYSIS BY PRODUCT TYPE
    51. INDIA MARKET ANALYSIS BY TECHNOLOGY
    52. JAPAN MARKET ANALYSIS BY TEST TYPE
    53. JAPAN MARKET ANALYSIS BY END USER
    54. JAPAN MARKET ANALYSIS BY PRODUCT TYPE
    55. JAPAN MARKET ANALYSIS BY TECHNOLOGY
    56. SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
    57. SOUTH KOREA MARKET ANALYSIS BY END USER
    58. SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
    59. SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
    60. MALAYSIA MARKET ANALYSIS BY TEST TYPE
    61. MALAYSIA MARKET ANALYSIS BY END USER
    62. MALAYSIA MARKET ANALYSIS BY PRODUCT TYPE
    63. MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
    64. THAILAND MARKET ANALYSIS BY TEST TYPE
    65. THAILAND MARKET ANALYSIS BY END USER
    66. THAILAND MARKET ANALYSIS BY PRODUCT TYPE
    67. THAILAND MARKET ANALYSIS BY TECHNOLOGY
    68. INDONESIA MARKET ANALYSIS BY TEST TYPE
    69. INDONESIA MARKET ANALYSIS BY END USER
    70. INDONESIA MARKET ANALYSIS BY PRODUCT TYPE
    71. INDONESIA MARKET ANALYSIS BY TECHNOLOGY
    72. REST OF APAC MARKET ANALYSIS BY TEST TYPE
    73. REST OF APAC MARKET ANALYSIS BY END USER
    74. REST OF APAC MARKET ANALYSIS BY PRODUCT TYPE
    75. REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
    76. SOUTH AMERICA MARKET ANALYSIS
    77. BRAZIL MARKET ANALYSIS BY TEST TYPE
    78. BRAZIL MARKET ANALYSIS BY END USER
    79. BRAZIL MARKET ANALYSIS BY PRODUCT TYPE
    80. BRAZIL MARKET ANALYSIS BY TECHNOLOGY
    81. MEXICO MARKET ANALYSIS BY TEST TYPE
    82. MEXICO MARKET ANALYSIS BY END USER
    83. MEXICO MARKET ANALYSIS BY PRODUCT TYPE
    84. MEXICO MARKET ANALYSIS BY TECHNOLOGY
    85. ARGENTINA MARKET ANALYSIS BY TEST TYPE
    86. ARGENTINA MARKET ANALYSIS BY END USER
    87. ARGENTINA MARKET ANALYSIS BY PRODUCT TYPE
    88. ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
    89. REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
    90. REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    91. REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
    92. REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    93. MEA MARKET ANALYSIS
    94. GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
    95. GCC COUNTRIES MARKET ANALYSIS BY END USER
    96. GCC COUNTRIES MARKET ANALYSIS BY PRODUCT TYPE
    97. GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
    98. SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
    99. SOUTH AFRICA MARKET ANALYSIS BY END USER
    100. SOUTH AFRICA MARKET ANALYSIS BY PRODUCT TYPE
    101. SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
    102. REST OF MEA MARKET ANALYSIS BY TEST TYPE
    103. REST OF MEA MARKET ANALYSIS BY END USER
    104. REST OF MEA MARKET ANALYSIS BY PRODUCT TYPE
    105. REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
    106. KEY BUYING CRITERIA OF HEALTHCARE
    107. RESEARCH PROCESS OF MRFR
    108. DRO ANALYSIS OF HEALTHCARE
    109. DRIVERS IMPACT ANALYSIS: HEALTHCARE
    110. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    111. SUPPLY / VALUE CHAIN: HEALTHCARE
    112. HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
    113. HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion)
    114. HEALTHCARE, BY END USER, 2024 (% SHARE)
    115. HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    116. HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
    117. HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
    118. HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    119. HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    120. BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES
    121. LIST OF ASSUMPTIONS
    122. North America MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    123. US MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    124. Canada MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    125. Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    126. Germany MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    127. UK MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    128. France MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    129. Russia MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    130. Italy MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    131. Spain MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    132. Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    133. APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    134. China MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    135. India MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    136. Japan MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    137. South Korea MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    138. Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    139. Thailand MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    140. Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    141. Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    142. South America MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    143. Brazil MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    144. Mexico MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    145. Argentina MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    146. Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    147. MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    148. GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    149. South Africa MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    150. Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY TEST TYPE, 2025-2035 (USD Billion)
      2. BY END USER, 2025-2035 (USD Billion)
      3. BY PRODUCT TYPE, 2025-2035 (USD Billion)
      4. BY TECHNOLOGY, 2025-2035 (USD Billion)
    151. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    152. ACQUISITION/PARTNERSHIP

HIV Diagnostics Market Segmentation

HIV Diagnostics Market By Test Type (USD Billion, 2019-2035)

Antibody Tests

Antigen Tests

Nucleic Acid Tests

HIV Diagnostics Market By End User (USD Billion, 2019-2035)

Hospitals

Diagnostic Laboratories

Home Care Settings

HIV Diagnostics Market By Product Type (USD Billion, 2019-2035)

Tests Kits

Instruments

Software

HIV Diagnostics Market By Technology (USD Billion, 2019-2035)

Elisa

Rapid Testing

Polymerase Chain Reaction

HIV Diagnostics Market By Regional (USD Billion, 2019-2035)

North America

Europe

South America

Asia Pacific

Middle East and Africa

HIV Diagnostics Market Regional Outlook (USD Billion, 2019-2035)

North America Outlook (USD Billion, 2019-2035)

North America HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

North America HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

North America HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

North America HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

North America HIV Diagnostics Market by Regional Type

US

Canada

US Outlook (USD Billion, 2019-2035)

US HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

US HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

US HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

US HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

CANADA Outlook (USD Billion, 2019-2035)

CANADA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

CANADA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

CANADA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

CANADA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

Europe Outlook (USD Billion, 2019-2035)

Europe HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

Europe HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

Europe HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

Europe HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

Europe HIV Diagnostics Market by Regional Type

Germany

UK

France

Russia

Italy

Spain

Rest of Europe

GERMANY Outlook (USD Billion, 2019-2035)

GERMANY HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

GERMANY HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

GERMANY HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

GERMANY HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

UK Outlook (USD Billion, 2019-2035)

UK HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

UK HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

UK HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

UK HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

FRANCE Outlook (USD Billion, 2019-2035)

FRANCE HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

FRANCE HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

FRANCE HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

FRANCE HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

RUSSIA Outlook (USD Billion, 2019-2035)

RUSSIA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

RUSSIA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

RUSSIA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

RUSSIA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

ITALY Outlook (USD Billion, 2019-2035)

ITALY HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

ITALY HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

ITALY HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

ITALY HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

SPAIN Outlook (USD Billion, 2019-2035)

SPAIN HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

SPAIN HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

SPAIN HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

SPAIN HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

REST OF EUROPE Outlook (USD Billion, 2019-2035)

REST OF EUROPE HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

REST OF EUROPE HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

REST OF EUROPE HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

REST OF EUROPE HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

APAC Outlook (USD Billion, 2019-2035)

APAC HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

APAC HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

APAC HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

APAC HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

APAC HIV Diagnostics Market by Regional Type

China

India

Japan

South Korea

Malaysia

Thailand

Indonesia

Rest of APAC

CHINA Outlook (USD Billion, 2019-2035)

CHINA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

CHINA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

CHINA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

CHINA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

INDIA Outlook (USD Billion, 2019-2035)

INDIA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

INDIA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

INDIA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

INDIA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

JAPAN Outlook (USD Billion, 2019-2035)

JAPAN HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

JAPAN HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

JAPAN HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

JAPAN HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

SOUTH KOREA Outlook (USD Billion, 2019-2035)

SOUTH KOREA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

SOUTH KOREA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

SOUTH KOREA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

SOUTH KOREA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

MALAYSIA Outlook (USD Billion, 2019-2035)

MALAYSIA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

MALAYSIA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

MALAYSIA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

MALAYSIA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

THAILAND Outlook (USD Billion, 2019-2035)

THAILAND HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

THAILAND HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

THAILAND HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

THAILAND HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

INDONESIA Outlook (USD Billion, 2019-2035)

INDONESIA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

INDONESIA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

INDONESIA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

INDONESIA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

REST OF APAC Outlook (USD Billion, 2019-2035)

REST OF APAC HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

REST OF APAC HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

REST OF APAC HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

REST OF APAC HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

South America Outlook (USD Billion, 2019-2035)

South America HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

South America HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

South America HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

South America HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

South America HIV Diagnostics Market by Regional Type

Brazil

Mexico

Argentina

Rest of South America

BRAZIL Outlook (USD Billion, 2019-2035)

BRAZIL HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

BRAZIL HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

BRAZIL HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

BRAZIL HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

MEXICO Outlook (USD Billion, 2019-2035)

MEXICO HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

MEXICO HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

MEXICO HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

MEXICO HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

ARGENTINA Outlook (USD Billion, 2019-2035)

ARGENTINA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

ARGENTINA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

ARGENTINA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

ARGENTINA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)

REST OF SOUTH AMERICA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

REST OF SOUTH AMERICA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

REST OF SOUTH AMERICA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

REST OF SOUTH AMERICA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

MEA Outlook (USD Billion, 2019-2035)

MEA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

MEA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

MEA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

MEA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

MEA HIV Diagnostics Market by Regional Type

GCC Countries

South Africa

Rest of MEA

GCC COUNTRIES Outlook (USD Billion, 2019-2035)

GCC COUNTRIES HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

GCC COUNTRIES HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

GCC COUNTRIES HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

GCC COUNTRIES HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

SOUTH AFRICA Outlook (USD Billion, 2019-2035)

SOUTH AFRICA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

SOUTH AFRICA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

SOUTH AFRICA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

SOUTH AFRICA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

REST OF MEA Outlook (USD Billion, 2019-2035)

REST OF MEA HIV Diagnostics Market by Test Type

Antibody Tests

Antigen Tests

Nucleic Acid Tests

REST OF MEA HIV Diagnostics Market by End User Type

Hospitals

Diagnostic Laboratories

Home Care Settings

REST OF MEA HIV Diagnostics Market by Product Type

Tests Kits

Instruments

Software

REST OF MEA HIV Diagnostics Market by Technology Type

Elisa

Rapid Testing

Polymerase Chain Reaction

 

 

Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions